Other languages Cartesian Therapeutics, Inc.

Equities

RNAC

US8162123025

Real-time Estimate Cboe BZX Other stock markets 11:05:19 2024-06-05 am EDT			5-day change	1st Jan Change
37 ^USD	+3.45%		+27.69%	+79.04%

Jun. 04	Oppenheimer Initiates Cartesian Therapeutics With Outperform Rating, $50 Price Target	MT
May. 24	Mizuho Securities Starts Cartesian Therapeutics With Buy Rating	MT

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Cartesian Gets Regenerative Medicine Advanced Therapy Label for Myasthenia Gravis Drug Candidate	May. 22
Cartesian Therapeutics, Inc. Receives FDA Regenerative Medicine Advanced Therapy Designation for Descartes-08 for the Treatment of Myasthenia Gravis	May. 22
Cartesian Therapeutics, Inc Receives Notice from Audentes Therapeutics, Inc of Astellas? Termination of the License and Development Agreement	Mar. 14
Cartesian Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07
Cartesian Therapeutics, Inc. Announces Resignation of Aymeric Sallin as Member of the Board of Director and Member of Compensation Committee	Mar. 05
Cartesian Therapeutics, Inc. Establishes New Corporate Headquarters and mRNA Cell Therapy cGMP Manufacturing Facility in Frederick, Maryland	Mar. 05
Cartesian Therapeutics Announces Positive Long-Term Follow-Up Data from Phase 2a Study of Lead mRNA Cell Therapy Candidate Descartes-08 in Patients with Myasthenia Gravis	Jan. 08
Cartesian Therapeutics, Inc. Announces Resignation of Scott D. Myers as Member of the Board, Compensation and Nominating and Corporate Governance Committees	Nov. 27
Selecta Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13
Sector Update: Health Care Stocks Gain in Late Afternoon Trading	Nov. 13
Selecta Biosciences Merges With Cartesian Therapeutics	Nov. 13
Cartesian Therapeutics, Inc. acquired Selecta Biosciences, Inc. for approximately $380 million, in a reverse merger transaction.	Nov. 12
Selecta Biosciences, Inc. and Swedish Orphan Biovitrum AB (Publ.) Enter into Amendment No. 1 to the License and Development Agreement	23-10-31
Peter Traber, Selecta Biosciences, Inc.?s Chief Medical Officer, Moves to Part-Time Status as Chief Medical Officer, Effective as of November 6, 2023	23-10-31
Selecta Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-17
Selecta Biosciences Says Phase 3 Studies of Investigational Gout Medicine Met Primary Efficacy Endpoints	23-05-31
Selecta Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04
Sector Update: Health Care Stocks Mixed Premarket Tuesday	23-03-21
Fed Meeting in Focus as US Equity Futures Extend Gains on Easing Bank Fears	23-03-21
Sector Update: Healthcare	23-03-21

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Cartesian Therapeutics, Inc.

Equities

RNAC

US8162123025

Other languages

Filters